Browse by category

Researchers at NYU Abu Dhabi have developed BRIDGE (Biodegradable aRchitected Internal DrainaGE), a biodegradable, 3D-printed gastric stent that could improve treatment for gastric leaks, a serious complication following bariatric surgery. By combining an advanced internal lattice design with biodegradable materials, the new device more than doubles drainage performance while potentially eliminating the need for a second procedure to remove the stent after healing, the resear

According to Professor Ahmed Ahmed, President of the British Obesity and Metabolic Specialist Society, robotic metabolic and bariatric surgery (rMBS) in the UK is still in the early stage of adoption. He said that there are several reasons why the speciality has been slower to adopt this technology compared with other surgical specialities such as urology, thoracic or colorectal. Ahmed Ahmed “I believe one of the reasons is so far there is no clear benefit of rMBS over the mo

Amylyx Pharmaceuticals has announced positive topline results from LUCIDITY, a 78-participant, multi-centre, randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. LUCIDITY met the FDA-agreed-upon primary endpoint demonstrat

An international study led by King’s College London, UK, has found that proposed new obesity definitions give greater insight into the ill health of metabolic bariatric surgery (MBS) candidates, compared with Body Mass Index (BMI). The study, found that people considered for MBS had marked variation in disease burden – the number and severity of diseases – and operation-related risks, despite having similar BMI. However, by reviewing clinical data from thousands of bariatric

Preoperative Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) neither augment nor detract from metabolic and bariatric surgery (MBS), at least for the first 12 months postoperatively, according to the study by researchers from the School of Medicine, University of California, San Francisco. GLP-1 RAs use has risen dramatically with some patients treated with GLP-1 RAs1 later pursue MBS. However, the researchers noted that preoperative GLP-1 RA exposure influences post-op

Minister of Health (MoH) of Kuwait has issued new standards for regulating metabolic bariatric surgeries (MBS) and non-surgical interventional procedures in public and private healthcare facilities. The Ministry has established a comprehensive regulatory framework based on clear standards covering healthcare facilities, medical practitioners, patient selection and assessment, follow-up procedures, and monitoring of outcomes and complications. The standards take effect immedia